Skip to main
STTK
STTK logo

Shattuck Labs (STTK) Stock Forecast & Price Target

Shattuck Labs (STTK) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Shattuck Labs Inc. is positioned favorably in the biotechnology sector due to its innovative development of SL-325, a potential first-in-class antibody aimed at treating inflammatory bowel disease (IBD) and other immune-mediated diseases, backed by strong expertise in protein engineering. The data indicates a significant increase in biologic use among patients with Crohn's disease (CD) and ulcerative colitis (UC) from 2007 to 2015, suggesting a growing market for effective treatments, which aligns with Shattuck's focus on high-efficacy therapeutics. Furthermore, the company's conservative estimates for the sales growth of SL-325 reflect confidence in robust market share expansion driven by consistent demand for effective therapies in the face of rising biologic usage rates.

Bears say

Shattuck Labs Inc faces challenges that may adversely impact its stock outlook due to the potential ineffectiveness and risks associated with its leading candidates, SL-325 and SL-425, which might not meet safety or efficacy expectations. Furthermore, the consistent underestimation of market growth and advanced therapy usage in inflammatory bowel disease (IBD) may hinder the commercial success of the company’s treatment approaches, as they may not align with market dynamics. As increasing utilization of biologics correlates with declining surgery rates, it raises concerns about market penetration and adoption for Shattuck Labs's therapies in a competitive landscape.

Shattuck Labs (STTK) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Shattuck Labs (STTK) Forecast

Analysts have given Shattuck Labs (STTK) a Buy based on their latest research and market trends.

According to 3 analysts, Shattuck Labs (STTK) has a Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Shattuck Labs (STTK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.